News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
285,265 Results
Type
Article (15124)
Company Profile (299)
Press Release (269836)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (80498)
Career Advice (164)
Deals (13451)
Drug Delivery (39)
Drug Development (50788)
Employer Resources (31)
FDA (5959)
Job Trends (5237)
News (146082)
Policy (10130)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (939)
Accelerated approval (19)
Adcomms (14)
Allergies (85)
Alliances (21968)
ALS (126)
Alzheimer's disease (1037)
Antibody-drug conjugate (ADC) (245)
Approvals (6158)
Artificial intelligence (267)
Autoimmune disease (119)
Automation (9)
Bankruptcy (108)
Best Places to Work (4623)
BIOSECURE Act (6)
Biosimilars (101)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (46)
Breast cancer (348)
Cancer (3192)
Cardiovascular disease (239)
Career advice (149)
Career pathing (8)
CAR-T (224)
CDC (5)
Cell therapy (577)
Cervical cancer (16)
Clinical research (43798)
Collaboration (1175)
Company closure (2)
Compensation (603)
Complete response letters (41)
COVID-19 (1104)
CRISPR (88)
C-suite (567)
Cystic fibrosis (113)
Data (4369)
Denatured (15)
Depression (93)
Diabetes (256)
Diagnostics (1405)
Digital health (13)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (197)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (218)
Earnings (31924)
Editorial (27)
Employer branding (4)
Employer resources (29)
Events (52103)
Executive appointments (629)
FDA (7742)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (994)
Gene editing (185)
Generative AI (22)
Gene therapy (497)
GLP-1 (507)
Government (1159)
Grass and pollen (3)
Guidances (170)
Healthcare (6829)
HIV (18)
Huntington's disease (43)
IgA nephropathy (75)
Immunology and inflammation (194)
Immuno-oncology (43)
Indications (72)
Infectious disease (1214)
Inflammatory bowel disease (157)
Inflation Reduction Act (10)
Influenza (40)
Intellectual property (169)
Interviews (18)
IPO (7396)
IRA (13)
Job creations (875)
Job search strategy (131)
JPM (40)
Kidney cancer (9)
Labor market (23)
Layoffs (243)
Leadership (10)
Legal (1410)
Liver cancer (42)
Longevity (11)
Lung cancer (435)
Lymphoma (251)
Machine learning (24)
Management (7)
Manufacturing (382)
MASH (132)
Medical device (2911)
Medtech (2920)
Mergers & acquisitions (6688)
Metabolic disorders (733)
Multiple sclerosis (104)
NASH (13)
Neurodegenerative disease (233)
Neuropsychiatric disorders (70)
Neuroscience (1968)
Neurotech (1)
NextGen: Class of 2026 (2101)
Non-profit (877)
Now hiring (31)
Obesity (333)
Opinion (125)
Ovarian cancer (132)
Pain (103)
Pancreatic cancer (166)
Parkinson's disease (232)
Partnered (12)
Patents (307)
Patient recruitment (346)
Peanut (44)
People (26811)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15511)
Phase 2 (20337)
Phase 3 (12865)
Pipeline (3379)
Policy (91)
Postmarket research (854)
Preclinical (6547)
Press Release (30)
Prostate cancer (147)
Psychedelics (50)
Radiopharmaceuticals (245)
Rare diseases (662)
Real estate (1498)
Recruiting (12)
Regulatory (9970)
Reports (19)
Research institute (983)
Resumes & cover letters (19)
Rett syndrome (24)
RNA editing (21)
RSV (17)
Schizophrenia (125)
Series A (185)
Series B (140)
Service/supplier (1)
Sickle cell disease (78)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (17)
Startups (2009)
State (1)
Stomach cancer (5)
Supply chain (35)
Tariffs (18)
The Weekly (62)
Vaccines (340)
Venture capital (69)
Weight loss (174)
Women's health (26)
Worklife (2)
Date
Today (23)
Last 7 days (316)
Last 30 days (1177)
Last 365 days (17916)
2026 (1975)
2025 (18178)
2024 (20668)
2023 (22561)
2022 (27117)
2021 (28082)
2020 (23585)
2019 (16462)
2018 (11956)
2017 (13904)
2016 (12004)
2015 (14559)
2014 (10548)
2013 (7620)
2012 (7724)
2011 (7771)
2010 (7554)
Location
Africa (159)
Alabama (65)
Alaska (2)
Arizona (73)
Arkansas (5)
Asia (18442)
Australia (3131)
California (7177)
Canada (1858)
China (787)
Colorado (249)
Connecticut (264)
Delaware (237)
Europe (39736)
Florida (915)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (404)
India (36)
Indiana (162)
Iowa (8)
Japan (230)
Kansas (80)
Kentucky (10)
Louisiana (7)
Maine (11)
Maryland (743)
Massachusetts (5641)
Michigan (110)
Minnesota (259)
Mississippi (4)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (33)
New Hampshire (21)
New Jersey (1662)
New Mexico (13)
New York (1777)
North Carolina (837)
North Dakota (6)
Northern California (3535)
Ohio (180)
Oklahoma (11)
Oregon (24)
Pennsylvania (1313)
Puerto Rico (9)
Rhode Island (26)
South America (222)
South Carolina (10)
Southern California (2837)
Tennessee (40)
Texas (922)
United States (23651)
Utah (97)
Virginia (137)
Washington D.C. (37)
Washington State (593)
West Virginia (1)
Wisconsin (48)
285,265 Results for "beam therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
JPM26: Beam, Cabaletta, More Zero In on Regulatory Alignment After Tumultuous Year
As biotechs faced investors at the J.P. Morgan Healthcare Conference this week, they emphasized agreement with the FDA on clinical trial design and regulatory pathways to approval. Atara, meanwhile, lamented the agency’s “complete reversal of position” after its therapy for a rare surgical complication was rejected.
January 19, 2026
·
6 min read
·
Heather McKenzie
Gene editing
‘Safer’ CRISPR: Base Editing Breaks Through in the Clinic as Beam, Verve Advance
Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative to conventional CRISPR. Clinical results have so far been promising.
May 5, 2025
·
9 min read
·
Shawna Williams
Gene editing
Beam’s Gene Editor Achieves ‘First Ever’ Genetic Correction in AATD
BEAM-302 “has set the bar for efficacy in this space,” William Blair analysts wrote in an investor note on Monday.
March 11, 2025
·
2 min read
·
Tristan Manalac
Wave To Work Alone on RNA Editor as AATD Picture Becomes Clearer
After GSK’s return of Wave Life Sciences’ WVE-006 as well as the mid-stage failure of Korro Bio’s candidate, the alpha-1 antitrypsin deficiency landscape is coming into focus, with Wave and Beam Therapeutics leading the way.
February 2, 2026
·
3 min read
·
Heather McKenzie
Sickle cell disease
Vertex, Beam Report SCD Cell and Gene Therapies Advances at ASH 2024
Vertex unveiled long-term durability data for Casgevy, while Beam presented Phase I/II findings for its investigational base editor BEAM-101, building up to a BLA by late 2026.
December 9, 2024
·
2 min read
·
Tristan Manalac
Gene editing
Patient Death Taints Otherwise Positive Data for Beam’s Sickle Cell Gene Therapy
BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, but a patient death underscores the need for less-toxic preconditioning treatments.
November 5, 2024
·
3 min read
·
Annalee Armstrong
Press Releases
CORRECTING and REPLACING: Gunze Medical and HistoSonics Enter into Exclusive Distributor Agreement in Japan for Noninvasive Platform and Proprietary Sonic Beam Therapy Using Histotripsy Technology
October 10, 2025
·
3 min read
Press Releases
Messenger RNA Market Research Report 2025-2035, Competitive Analysis of Pfizer, GSK, Arcturus Therapeutics, AstraZeneca, Beam Therapeutics, Moderna, Oncotelic, SK Bioscience, Sangamo, Sanofi CureVac
June 11, 2025
·
6 min read
Business
Genome Medical Supporting Beam Therapeutics on its Sickle Cell Disease Clinical Trial
Genome Medical, the leading telehealth provider of genetic services and solutions, is teaming up with Beam Therapeutics Inc. to provide access to genetic counseling for participants in Beam’s BEACON clinical trial evaluating BEAM-101 as a potential treatment for sickle cell disease (SCD).
May 25, 2023
·
2 min read
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
1 of 28,527
Next
